The ΔT/ΔC analysis indicated that targeting SHP2 in cancer cells induced less anti-tumor immunity than SHP099 (Fig. 7a), suggesting SHP099 mediated anti-tumor effects may also be mediated by SHP2 inhibition in immune or stromal cells. The gene discussed is PTPN11; the disease is cancer.